| Literature DB >> 34917159 |
Nasim Golkar1,2, Yousef Ashoori3,4,5, Reza Heidari2, Navid Omidifar6, Seyedeh Narjes Abootalebi3,7, Milad Mohkam3,8, Ahmad Gholami2,3.
Abstract
The wound is a break in the integrity of the skin produced by injury, illness, or operation. Wound healing is an essential dynamic biological/physiological process that occurs in response to tissue damage. The huge health, economic, and social effects of wounds on patients and societies necessitate the research to find novel potential therapeutic agents in order to promote wound healing. Postbiotics, the newest member of the biotics family, are valuable functional bioactive substances produced by probiotics through their metabolic activity, which have several beneficial properties, including immunomodulatory, anti-inflammatory, antimicrobial, and angiogenesis characteristics, resulting in acceleration of wound healing. In the current study, three topical cold cream formulations containing postbiotics obtained from Lactobacillus fermentum, Lactobacillus reuteri, or Bacillus subtilis sp. natto probiotic strains were prepared. The effectiveness and wound healing activity of the developed postbiotics cold cream formulations were investigated compared to cold cream without postbiotics and no treatment via wound closure investigation, hydroxyproline content assay, and histological assessment in 25 Sprague Dawley rats divided into five groups. Interestingly, analysis of the results revealed that all three formulations containing postbiotics significantly accelerated the wound healing process. However, in general, the Bacillus subtilis natto cold cream manifested a better wound healing property. The pleasing wound healing characteristics of the topical postbiotics cold creams through the in vivo experiment suggest that formulations containing postbiotics can be considered as a promising nominee for wound healing approaches.Entities:
Year: 2021 PMID: 34917159 PMCID: PMC8670929 DOI: 10.1155/2021/8577116
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Different rat groups treated with various topical postbiotics formulations.
| Rat groups | The topical formulation administered to the rat group |
|---|---|
|
| No treatment (control) |
|
| Cold cream without postbiotics |
|
| Formulation 1 ( |
|
| Formulation 2 ( |
|
| Formulation 3 ( |
Scores of the changes in histopathological features of the skin.
| Score | Changes in histopathological features of skin tissue |
|---|---|
|
| There is no apparent change |
|
| Mild changes |
|
| Moderate changes |
|
| Severe changes |
Figure 1Qualitative trend of wound healing process of different rat groups receiving no treatment (control), cold cream alone, Lactobacillus fermentum postbiotic cold cream, Lactobacillus Reuteri postbiotic cold cream, or Bacillus Subtilis sp. natto postbiotic cold cream. The photos were taken at Day 2, Day 5, Day 11, and Day 14 of treatment.
Figure 2Wound sizes (mm) following treatment of different rat groups (G1 to G5) with various formulations. Data are expressed as mean ± SD (standard deviation).
Figure 3Wound healing percentages following treatment of different rat groups (G1 to G5) with various formulations. Data are expressed as mean ± SD (standard deviation).
Wound healing percentages in various days of a 14-day treatment of five rat groups with three postbiotic cold cream formulations, cold cream formulation alone, and no treatment (control).
| Rat groups | No treatment (control) | Cold cream alone | L. | L. |
|
|---|---|---|---|---|---|
| Day | |||||
|
| 6.195 ± 0.330 | 7.800 ± 0.350 | 7.080 ± 0.600 | 5.310 ± 0.300 | 9.734 ± 0.400 |
|
| 21.239 ± 1.000 | 29.203 ± 1.000 | 30.088 ± 0.900 | 11.504 ± 0.710 | 20.354 ± 0.350 |
|
| 19.469 ± 0.890 | 23.009 ± 0.890 | 46.902 ± 1.210 | 23.009 ± 1.300 | 30.088 ± 1.100 |
|
| 23.894 ± 0.710 | 29.203 ± 0.710 | 46.017 ± 0.840 | 34.513 ± 2.000 | 33.628 ± 0.710 |
|
| 24.1 ± 0.840 | 34.513 ± 0.840 | 52.212 ± 0.840 | 48.672 ± 1.520 | 53.982 ± 2.700 |
|
| 38.053 ± 0.800 | 41.593 ± 0.800 | 60.177 ± 2.550 | 66.372 ± 0.890 | 67.256 ± 0.890 |
|
| 38.938 ± 1.500 | 48.672 ± 1.820 | 76.991 ± 2.170 | 78.761 ± 0.450 | 72.566 ± 0.840 |
|
| 56.637 ± 1.340 | 67.257 ± 1.340 | 76.995 ± 1.300 | 82.301 ± 0.100 | 79.646 ± 0.550 |
|
| 57.522 ± 3.000 | 65.487 ± 3.320 | 84.956 ± 0.550 | 88.495 ± 0.890 | 93.805 ± 1.150 |
|
| 74.336 ± 4.000 | 75.221 ± 3.030 | 91.150 ± 1.000 | 100.00 ± 0.010 | 100.00 ± 0.850 |
Figure 4Determination of wound hydroxyproline production as an indicator of collagen levels measured at the end of Day 14 following administration of three different postbiotics cold creams (Lactobacillus fermentum postbiotic cold cream, Lactobacillus Reuteri postbiotic cold cream, or Bacillus subtilis sp. natto postbiotic cold cream), cold cream without postbiotics, and no treatment (control) on the excised wounds in rat model. Result values are expressed as means ± standard deviation. P value < 0.0001, P value < 0.001, and P value < 0.05; ns denotes not significant compared to untreated wound tissue. ###P value < 0.001 and #P value < 0.05.
Figure 5Skin tissue histopathological assessment of different rat groups at the end of Day 14 through hematoxylin-eosin staining. (a) Rat group receiving no treatment (control). (b) Rat group receiving cold cream alone. (c) Rat group receiving Lactobacillus fermentum postbiotic cold cream. (d) Rat group receiving Lactobacillus Reuteri postbiotic cold cream. (e) Rat group receiving Bacillus subtilis sp. natto postbiotic cold cream.
Skin histopathological changes at the end of Day 14 in different rat groups following 14-day administration of various formulations on wound tissues.
| No treatment (control) | Cold cream |
|
|
| |
|---|---|---|---|---|---|
|
| Incomplete | Incomplete (deep) | Incomplete (super) | Complete | Complete |
|
| ++ | ++ | ++ | − | + |
|
| ++ | ++ | + | − | − |
|
| ++ | + | + | + | + |
− means no significant change (P > 0.05); + and ++ mean mild (P < 0.05) and moderate (P < 0.001) histopathological significant changes, respectively. Significant histopathological changes in comparison to the no-treatment group (control) (P < 0.05).